Another UK Biotech Snapped Up As Neurocrine Buys Diurnal
US Firm Paying Just £48m
Lack of scale, the need for further funding and problems getting reimbursement for its adrenal insufficiency products left the Wales-headquartered firm vulnerable to a takeover and San Diego's Neurocrine has swooped.
